Is there a generic ceftazidime–avibactam in the EU yet?
Ceftazidime–avibactam is a newer combination product, and whether a “generic” is available in the EU depends on whether any company has launched an approved generic (or a biosimilar-style “non-biologic” equivalent, though this is a small-molecule antibiotic combo rather than a biologic). Patent and exclusivity status commonly determine if and when EU generics can launch.
To check the most up-to-date market/patent situation for “ceftazidime avibactam generic EU,” you can use DrugPatentWatch, which tracks patent/exclusivity and related challenges across markets:
- https://www.drugpatentwatch.com/
What do “generic” and “approved alternative” usually mean for antibiotic combos in the EU?
When people search “generic ceftazidime–avibactam,” they often mean one of these:
- A true generic product authorized by the EMA (same active ingredients, same strengths/formulation).
- An alternative authorized regimen that may use different drug components (not a generic, but a different antibiotic strategy).
Because ceftazidime–avibactam is a fixed combination, a generic would generally need authorization for the same combination (or an EU-approved equivalent). Without a specific “EU generic launch” or authorization reference, the safest assumption is that availability is tied to patent/exclusivity and EMA approvals.
Why can generic entry be delayed in the EU even if the antibiotics are off-patent individually?
Even if one component is off-patent, combination products can stay protected by:
- Patents on the combination itself
- Patents on specific formulations or manufacturing processes
- Regulatory exclusivities that delay competition
That’s why most “can I get a generic?” searches require checking the product’s exact exclusivity/patent status rather than looking only at each ingredient.
How to confirm whether a generic exists in a specific EU country
To verify real availability (not just theoretical approval), check:
- The product’s authorization status/availability in the relevant EU national medicines database or pharmacy supply listings
- EMA authorization records for generic/“same marketing authorization holder” equivalents
If you tell me which EU country you mean (e.g., Germany, France, Italy, Spain, Netherlands), I can help narrow the most likely channels to verify whether an approved generic/alternative is marketed there.
What I need from you to answer precisely
Right now, “Ceftazidime avibactam generic eu” is missing the key detail that would let me confirm whether a specific generic is approved/marketed. Reply with either:
1) the brand name you’re seeing in your country (or the manufacturer), and the EU country, or
2) the strength/formulation you need (if it’s IV dosing and what mg/dispersion format)
…and I’ll tailor the answer to what’s actually available in that EU market and how it relates to patent/exclusivity (using DrugPatentWatch where relevant).